 |
|
|
|
Finadyne Solution contains Flunixin meglumine which is a potent, non-steroidal, non-narcotic analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic properties.
In the horse, Finadyne Solution is indicated for the alleviation of inflammation and pain associated with musculo-skeletal disorders. It is also indicated for the alleviation of visceral pain associated with colic.
In cattle, Finadyne Solution is indicated for the control of acute inflammation associated with respiratory disease. It has also been shown to have some benefit in the treatment of experimental acute bovine pulmonary emphysema (Fog Fever).
In cattle, Finadyne may be used as adjunctive therapy in the treatment of acute mastitis.
In pigs, Finadyne Solution is indicated for use as an adjunctive therapy in the treatment of swine respiratory diseases
|
|
Presentation
A clear, light yellow, sterile solution for injection containing 50 mg flunixin, as flunixin meglumine BP (Vet), and 5 mg phenol Ph Eur as a preservative, per ml.
Uses
Flunixin meglumine is a potent, non-steroidal, non-narcotic analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic properties.
In the horse, Finadyne Solution is indicated for the alleviation of inflammation and pain associated with musculo-skeletal disorders. It is also indicated for the alleviation of visceral pain associated with colic.
In cattle, Finadyne Solution is indicated for the control of acute inflammation associated with respiratory disease. It has also been shown to have some benefit in the treatment of experimental acute bovine pulmonary emphysema (Fog Fever).
In cattle, Finadyne may be used as adjunctive therapy in the treatment of acute mastitis.
In pigs, Finadyne Solution is indicated for use as an adjunctive therapy in the treatment of swine respiratory diseases
|
|
Dosage and administration
For use in equine musculo-skeletal disorders, the recommended dosage is 1 ml Finadyne Solution per 45 kg bodyweight (equivalent to 1.1 mg flunixin per kg) injected intravenously once daily for up to five days according to clinical response.
For use in equine colic, the recommended dosage is 1 ml Finadyne Solution per 45 kg bodyweight (equivalent to 1.1 mg flunixin per kg) by intravenous injection. Treatment may be repeated once or twice if colic recurs. The cause of colic should be determined and treated with concomitant therapy.
For the treatment of endotoxaemia or septic shock associated with gastric torsion and with other conditions in which circulation of blood to the gastrointestinal tract is impaired, the recommended dosage is 1 ml per 200 kg bodyweight (0.25 mg/kg) administered every 6–8 hours.
For use in bovine acute inflammatory conditions, the recommended dosage is 2 ml Finadyne Solution per 45 kg bodyweight (equivalent to 2.2 mg flunixin per kg) injected intravenously and repeated as necessary at 24 hour intervals for up to 5 consecutive days. The cause of the acute inflammatory condition should be determined and treated with concomitant therapy.
For use in pigs, the recommended dosage is 2 ml Finadyne Solution per 45 kg bodyweight (equivalent to 2.2 mg flunixin/kg) once by intramuscular injection, in the neck, in conjunction with appropriate antimicrobial therapy. The injection volume should be limited to a maximum of 5 ml per injection site.
|
|
Contra-indications, warnings, etc
Animals must not be slaughtered for human consumption during treatment.
Cattle may be slaughtered for human consumption only from 5 days after the last treatment.
Pigs may be slaughtered for human consumption after 22 days from the last treatment.
Horses may be slaughtered for human consumption only from 7 days after the last treatment.
Milk for human consumption must not be taken during treatment. Milk for human consumption may only be taken from cattle after 24 hours from the last treatment.
Do not exceed the stated dose or the duration of treatment.
Do not administer to pregnant mares. Do not administer to pregnant sows, gilts at mating and in breeding boars. Safety studies in pregnant mares or sows have not been conducted.
Avoid intra-arterial injection.
It is perferable that NSAIDs which inhibit prostaglandin synthesis are not administered to animals which are undergoing general anaesthesia until fully recovered.
Use is contra-indicated in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastro-intestinal ulceration or bleeding, or where there is hypersensitivity to the product.
Use in any animal less than 6 weeks of age or in aged animals may involve additional risk. If such use cannot be avoided animals may require a reduced dosage and careful clinical management. The product should not be used in piglets weighing less than 6 kg.
Do not use in hypovolaemic animals, except in the case of endotoxaemia or septic shock.
Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs which can lead to toxic effects.
Do not administer other NSAIDs concurrently or within 24 hours of each other.
Concurrent administration of potentially nephrotoxic drugs should be avoided.
For animal treatment only.
Keep out of the reach of children.
Pharmaceutical precautions
Do not store above 25°C. Do not freeze.
Following withdrawal of the first dose, use within 28 days. Discard unused material. Unused product and any waste material should be disposed of in accordance with guidance from an appropriate waste regulation authority.
|
|
Legal category
POM-V (previously POM).
Packaging Quantities
50 ml and 100 ml glass vials.
Further information
Flunixin meglumine is also presented as Finadyne Granules and Finadyne Paste which may be used as an alternative to Finadyne Solution in musculo-skeletal indications in the horse. A suggested dosage regime is an initial injection of Finadyne Solution followed by Finadyne Granules or Finadyne Paste on subsequent days.
Studies in horses have shown onset of activity occurs two hours after parenteral administration when used in musculo-skeletal disorders. Peak response occurs between 12 and 16 hours and the duration of activity is 24 to 36 hours. When used in equine colic, studies have shown alleviation of pain within 15 minutes in many cases. During clinical studies, approximately 10% of the horses required one or two additional treatments.
Veterinary Surgeons administering NSAIDs to racehorses should refer to Section 4.4 of the RCVS Guide to Professional Conduct. Section 4.4.7 states, ``If a veterinarian recommends the discontinuance of any substance . . . not less than eight days before racing (even though such a period may be longer than is necessary in many instances) he should be able to feel sure that he has catered for all but the most exceptional cases''.
Marketing authorisation number
Vm 0201/4009.
|
|
|
